Diabetes, Vol 46, Issue 12 2096-2101, Copyright © 1997 by American Diabetes Association

ARTICLES

Circulating vascular cell adhesion molecule-1 (VCAM-1) in atherosclerotic NIDDM patients

M Otsuki, K Hashimoto, Y Morimoto, T Kishimoto and S Kasayama
Department of Medicine III, Osaka University Medical School, Suita-City, Japan.

Vascular cell adhesion molecule-1 (VCAM-1) has been shown to be highly expressed in atherosclerotic lesions. Although the soluble form of VCAM-1 (sVCAM-1) is detected in human sera, the relation between the degree of atherosclerosis and serum sVCAM-1 level has not been defined. In the present study, sVCAM-1 concentrations were measured in sera from 101 Japanese NIDDM patients. The mean +/- SD serum sVCAM-1 concentration in 26 patients with symptomatic atherosclerotic vascular diseases (789 +/- 187 ng/ml) was higher than that in 75 patients without the disease (664 +/- 175 ng/ml). Among the 101 NIDDM patients, 56 had atherosclerotic change of the carotid arteries, based on the evaluation by high-resolution B-mode ultrasonography. Their sVCAM-1 level was 759 +/- 201 ng/ml, higher than that in 45 patients without any detectable atherosclerosis of the carotid arteries (619 +/- 130 ng/ml). In addition, there was a positive correlation between sVCAM-1 concentration and thickness of the intimal plus medial complex (IMT) of the carotid arteries in the NIDDM patients (r = 0.41, P < 0.0001). Multivariate regression analysis revealed significant predictors of mean IMT value to be sVCAM-1 concentration (F = 62.88, P = 0.0001) and age (F = 9.59, P = 0.0026). By contrast, sVCAM-1 concentration was not increased in nondiabetic patients with atherosclerotic change of the carotid arteries (668 +/- 191 ng/ml; n = 36) compared with those without the atherosclerotic change (632 +/- 177 ng/ml; n = 28), and there was no correlation between sVCAM-1 level and IMT of the carotid arteries in the nondiabetic subjects. These results indicate that circulating sVCAM-1 may be a marker of atherosclerotic lesions in NIDDM patients with symptomatic and asymptomatic atherosclerosis.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. C. Schramm, T. Dinh, and A. Veves Microvascular changes in the diabetic foot. International Journal of Lower Extremity Wounds, September 1, 2006; 5(3): 149 - 159. [Abstract] [PDF]

				J. T. Wu and L. L. Wu Association of Soluble Markers with Various Stages and Major Events of Atherosclerosis Ann. Clin. Lab. Sci., January 1, 2005; 35(3): 240 - 250. [Abstract] [Full Text] [PDF]

				J. Okapcova and D. Gabor The Levels of Soluble Adhesion Molecules in Diabetic and Nondiabetic Patients with Combined Hyperlipoproteinemia and the Effect of Ciprofibrate Therapy Angiology, November 1, 2004; 55(6): 629 - 639. [Abstract] [PDF]

				J. Okapcova and D. Gabor The Levels of Soluble Adhesion Molecules in Diabetic and Nondiabetic Patients with Combined Hyperlipoproteinemia and the Effect of Ciprofibrate Therapy Angiology, November 1, 2004; 55(6): 629 - 639. [Abstract] [PDF]

				A. Ceriello, L. Quagliaro, L. Piconi, R. Assaloni, R. Da Ros, A. Maier, K. Esposito, and D. Giugliano Effect of Postprandial Hypertriglyceridemia and Hyperglycemia on Circulating Adhesion Molecules and Oxidative Stress Generation and the Possible Role of Simvastatin Treatment Diabetes, March 1, 2004; 53(3): 701 - 710. [Abstract] [Full Text] [PDF]

				M. Sacco, F. Pellegrini, M. C. Roncaglioni, F. Avanzini, G. Tognoni, and A. Nicolucci Primary Prevention of Cardiovascular Events With Low-Dose Aspirin and Vitamin E in Type 2 Diabetic Patients: Results of the Primary Prevention Project (PPP) trial Diabetes Care, December 1, 2003; 26(12): 3264 - 3272. [Abstract] [Full Text] [PDF]

				N. Marx, J. Froehlich, L. Siam, J. Ittner, G. Wierse, A. Schmidt, H. Scharnagl, V. Hombach, and W. Koenig Antidiabetic PPAR{gamma}-Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Patients With Coronary Artery Disease Arterioscler. Thromb. Vasc. Biol., February 1, 2003; 23(2): 283 - 288. [Abstract] [Full Text] [PDF]

				T. Skoog, W. Dichtl, S. Boquist, C. Skoglund-Andersson, F. Karpe, R. Tang, M.G. Bond, U. de Faire, J. Nilsson, P. Eriksson, et al. Plasma tumour necrosis factor-{alpha} and early carotid atherosclerosis in healthy middle-aged men Eur. Heart J., March 1, 2002; 23(5): 376 - 383. [Abstract] [Full Text] [PDF]

				W. Bagg, C. Ferri, G. Desideri, G. Gamble, P. Ockelford, and G. D. Braatvedt The Influences of Obesity and Glycemic Control on Endothelial Activation in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5491 - 5497. [Abstract] [Full Text] [PDF]

				X. Xu, M. Otsuki, H. Saito, S. Sumitani, H. Yamamoto, N. Asanuma, H. Kouhara, and S. Kasayama PPAR{alpha} and GR Differentially Down-Regulate the Expression of Nuclear Factor-{kappa}B-Responsive Genes in Vascular Endothelial Cells Endocrinology, August 1, 2001; 142(8): 3332 - 3339. [Abstract] [Full Text] [PDF]

				L. Ryysy and H. Yki-Järvinen Improvement of Glycemic Control by 1 Year of Insulin Therapy Leads to a Sustained Decrease in sE-Selectin Concentrations in Type 2 Diabetes Diabetes Care, March 1, 2001; 24(3): 549 - 554. [Abstract] [Full Text]

				M. Otsuki, H. Saito, X. Xu, S. Sumitani, H. Kouhara, T. Kishimoto, and S. Kasayama Progesterone, but Not Medroxyprogesterone, Inhibits Vascular Cell Adhesion Molecule-1 Expression in Human Vascular Endothelial Cells Arterioscler. Thromb. Vasc. Biol., February 1, 2001; 21(2): 243 - 248. [Abstract] [Full Text] [PDF]

				W.S. Weintraub and D.G. Harrison C-reactive protein, inflammation and atherosclerosis: do we really understand it yet? Eur. Heart J., June 2, 2000; 21(12): 958 - 960. [PDF]

				R. Marfella, K. Esposito, R. Giunta, G. Coppola, L. De Angelis, B. Farzati, G. Paolisso, and D. Giugliano Circulating Adhesion Molecules in Humans : Role of Hyperglycemia and Hyperinsulinemia Circulation, May 16, 2000; 101(19): 2247 - 2251. [Abstract] [Full Text] [PDF]

				L. Feng, D. M. Stern, and J. Pile-Spellman Human Endothelium: Endovascular Biopsy and Molecular Analysis Radiology, September 1, 1999; 212(3): 655 - 664. [Abstract] [Full Text]

				A. M. Schmidt, S. D. Yan, J.-L. Wautier, and D. Stern Activation of Receptor for Advanced Glycation End Products : A Mechanism for Chronic Vascular Dysfunction in Diabetic Vasculopathy and Atherosclerosis Circ. Res., March 19, 1999; 84(5): 489 - 497. [Abstract] [Full Text] [PDF]